Cindy Pan focuses her practice on initial public offerings and other capital markets transactions on the Hong Kong Stock Exchange, listing rules and securities regulations compliance and other general corporate matters.
Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).
Harbour BioMed Announces $105.3 Million Share Subscription Agreement With AstraZeneca
March 21, 2025
Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its share subscription agreement with AstraZeneca.
Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.
ImmuneOnco Biopharmaceuticals – HK$319 Million IPO
September 5, 2023
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.
Laekna Announces Largest 18A IPO Year to Date at HK$791 Million
June 29, 2023
Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.
